Considerations for Pso and PsA telemedicine in the time of COVID-19, and its impact for clinicians and patients

CONFRONTING CHALLENGES FOR THE PEACE WITHIN

Discover groundbreaking insights from leading experts, with videos, articles and more >

Pso: psoriasis; PsA: psoriatic arthritis
Janssen Pharmaceutical Companies of Johnson & Johnson in EMEA
CP-180586 September 2020
LETTER TO THE EDITOR

Effects of lockdown on health of patients with severe atopic dermatitis treated with dupilumab

Dear Editor,

Use of dupilumab as treatment for severe adult atopic dermatitis (AD) increased over time since its introduction in September 2018, due to its established efficacy. AD is one of the most common chronic inflammatory skin disease affecting up to 14.3% of adults, with 63.3% of these cases first appearing before 18 years of age.1 Patients’ disease burden is important with high rate of discomfort, less confidence in daily life activities and psycho-social distress. The introduction of dupilumab changed the natural history of this disease, drastically improving AD manifestations and therefore quality of life.2

In 2020, the COVID-19 epidemics started spreading in Italy, leading the Government to establish urgent and strict restriction measures in avoid to contain the spread of the infection. Lombardy region has been the first epicentre of the health crisis starting mid-February. Shortly after, the virus spread to other regions with a relevant number of infected patients, forcing a general lockdown from March 9 to May 4. During this time span, individuals were allowed to leave the household only for grocery shopping and proven basic necessities, while only first-need shops and services were allowed to operate. In the hospital setting, only urgent visits were performed, and our ward was only available to dispense dupilumab and assess severe cases.

We describe our experience in the Dermatology Unit of our hospital in Milan, observing how lockdown period influenced clinical and psychological aspects of patient with severe AD in therapy with dupilumab.

The cohort was made up of 106 out of 252 adult patients with severe AD in treatment with dupilumab in our centre (Table 1). Inclusion criteria were a follow up visit during or shortly after the lockdown period (March 1–June 15) and correct adherence to the therapy for at least 1 year.

After clinical evaluation, we calculated Eczema Area and Severity Index (EASI) and asked each patient to complete a survey including Numeric Rating Scale (NRS) for the evaluation of itch, NRS for evaluation of sleep quality, Dermatology Life Quality Index (DLQI) and Patient-Oriented Eczema Measure (POEM); then we also assessed disease’s psychological impact on quality of life and Hospital Anxiety and Depression Scale (HADS) for depression (HADS-D) and anxiety (HADS-A).

We decided to exclude patients under therapy for <1 year because we felt that clinical improvement and perception of better quality of life could be over-felt by the patient during this phase, inducing a bias.

We performed a retrospective analysis comparing surveys collected during the lockdown time against baseline from the same patient, seeking for any significant difference. Results are show in Table 1.

We used paired t student test to statistically validate the results ($\alpha = 1\% = 0.05$).

According to the literature, all collected parameters should have improved at the same time to different degrees until 52th weeks of treatment with dupilumab.3 Instead, HADS-D score declined by 23% with statistical significance ($P < 0.0005$), even though the disease severity decreased, with a calculated EASI improving on average by 23% ($P < 0.0005$) over the considered period.

| Scores | Mean predupilumab | Mean Prelockdown | Mean Postlockdown | Variation % | $P$-value |
|--------|-------------------|-----------------|-----------------|-------------|-----------|
| EASI   | 31.7              | 3.89            | 3.01            | $-23\%$    | $<0.005$  |
| HADS-D | 7                 | 2.92            | 3.60            | $23\%$     | $<0.005$  |
| HADS-A | 7.8               | 3.38            | 3.51            | $3.8\%$    | *         |
| ITCH NRS | 8.8              | 2.89            | 2.65            | $-0\%$     | *         |
| SLEEP NRS | 6.9              | 0.63            | 0.62            | $0\%$      | *         |
| DLQI   | 16.2              | 3.10            | 3.18            | $2.6\%$    | *         |
| POEM   | 21.5              | 6.93            | 6.42            | $-7.4\%$   | *         |

Prelockdown: December 1 – February 29.
Postlockdown: March 1 – June 15.

*Other changes in variables considered were not statistically relevant.
In contrast, we observed a diffused decline of patients’ psychological status (HADS-D) during the lockdown phase, with scores worsening in comparison with those from the prelockdown. They generally felt depressed, grieve, slowed down and tired in the daily routine and more frequently in a bad mood. This worsening of HADS-D is unexpected.

In effect, our data show a paradoxical effect: a marked AD clinical improvement as assessed by means of EASI with a decline in the psychological scores. This may be explained by the confinement in the households with less recreational activities, fear of contagion and loss of positive vision for the future.

Our observations are not isolated, as other published studies reported an increase in anxiety during lockdown in patients in treatment with biologic therapies for other conditions.4

Conflicts of interest
None declared.

Funding sources
None.

References
1. Nettis E et al. A multicentric study on prevalence of clinical patterns and clinical phenotypes in adult atopic dermatitis. J Investig Allergol Clin Immunol 2020; 30. https://doi.org/10.18176/jiaci.0519
2. Ferrucci SM, Casazza G, Angileri L et al. Clinical response and quality of life in patients with severe atopic dermatitis treated with dupilumab: a single-center real-life experience. J Clin Med 2020; 9: 791.
3. Deleuran M, Thaçi D, Beck LA et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol 2020; 82: 377–388.
4. Rob F, Hugo J, Tivadar S et al. Compliance, safety concerns and anxiety in patients treated with biologics for psoriasis during the COVID-19 pandemic national lockdown: a multicenter study in the Czech Republic [published online ahead of print, 2020 Jun 27]. J Eur Acad Dermatol Venereol 2020. https://doi.org/10.1111/jdv.16771

DOI: 10.1111/jdv.16955